Qiagen NV
QGEN48.290USD
-0.160-0.33%
終値 01/09, 16:00（ET）15分遅れの株価
10.45B時価総額
25.83直近12ヶ月PER
詳細情報 Qiagen NV 企業名
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Qiagen NVの企業情報
企業コードQGEN
会社名Qiagen NV
上場日Sep 01, 1996
最高経営責任者「CEO」Bernard (Thierry)
従業員数5765
証券種類Ordinary Share
決算期末Sep 01
本社所在地Hulsterweg 82
都市VENLO
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国Netherlands
郵便番号5912 PL
電話番号31773556600
ウェブサイトhttps://www.qiagen.com/
企業コードQGEN
上場日Sep 01, 1996
最高経営責任者「CEO」Bernard (Thierry)
Qiagen NVの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+143556.00%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+134537.00%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-227680.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+4436.00%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+3835.00%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
+3973.00%
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
24.00
--
Dr. Toralf Haag, Ph.D.
Dr. Toralf Haag, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Eva Pisa, Ph.D.
Dr. Eva Pisa, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Bert van Meurs
Mr. Bert van Meurs
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+143556.00%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+134537.00%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-227680.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+4436.00%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+3835.00%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
+3973.00%
収益内訳
通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
事業別USD
会社名
収益
比率
Consumables and Related Revenues
481.20M
90.35%
Instrumentation
51.38M
9.65%
地域別USD
会社名
収益
比率
United States
286.67M
53.83%
Europe & Middle East & Africa
172.58M
32.40%
Asia, Pacific & Rest of the World
73.33M
13.77%
事業別
地域別
事業別USD
会社名
収益
比率
Consumables and Related Revenues
481.20M
90.35%
Instrumentation
51.38M
9.65%
株主
更新時刻: Mon, Nov 17
更新時刻: Mon, Nov 17
株主統計
種類
株主統計
株主統計
比率
Wellington Management Company, LLP
10.76%
MFS Investment Management
10.56%
The Vanguard Group, Inc.
4.30%
T. Rowe Price International Ltd
3.47%
DWS Investment GmbH
2.13%
他の
68.78%
株主統計
株主統計
比率
Wellington Management Company, LLP
10.76%
MFS Investment Management
10.56%
The Vanguard Group, Inc.
4.30%
T. Rowe Price International Ltd
3.47%
DWS Investment GmbH
2.13%
他の
68.78%
種類
株主統計
比率
Investment Advisor/Hedge Fund
48.67%
Investment Advisor
26.05%
Research Firm
5.08%
Pension Fund
1.63%
Sovereign Wealth Fund
1.60%
Hedge Fund
1.10%
Bank and Trust
1.09%
Individual Investor
0.44%
Insurance Company
0.07%
他の
14.27%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
988
176.43M
85.64%
-25.04M
2025Q3
996
177.81M
82.00%
-32.33M
2025Q2
996
189.55M
87.53%
+6.64M
2025Q1
1017
179.03M
82.67%
+27.58M
2024Q4
1010
129.03M
59.70%
-70.06M
2024Q3
1010
183.22M
84.72%
-23.62M
2024Q2
1002
184.34M
84.75%
+8.40M
2024Q1
988
165.20M
76.61%
-7.18M
2023Q4
993
165.11M
76.72%
-10.52M
2023Q3
987
159.93M
74.32%
-12.21M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Wellington Management Company, LLP
23.33M
10.76%
-2.69M
-10.35%
Sep 30, 2025
MFS Investment Management
22.91M
10.56%
-570.88K
-2.43%
Sep 30, 2025
The Vanguard Group, Inc.
9.33M
4.3%
+169.45K
+1.85%
Sep 30, 2025
T. Rowe Price International Ltd
7.52M
3.47%
+1.59M
+26.73%
Sep 30, 2025
DWS Investment GmbH
4.62M
2.13%
+1.32M
+39.94%
Sep 30, 2025
EARNEST Partners, LLC
4.21M
1.94%
+6.14K
+0.15%
Sep 30, 2025
Amundi Asset Management, SAS
4.15M
1.91%
+170.89K
+4.30%
Sep 30, 2025
Boston Partners
4.02M
1.85%
+594.42K
+17.37%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.98M
1.84%
-16.38M
-80.43%
Sep 30, 2025
BofA Global Research (US)
3.61M
1.66%
+2.63M
+269.19%
Oct 21, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
First Trust Nasdaq Lux Digi Health Solutions ETF
4.04%
Global X Genomics & Biotechnology ETF
3.81%
Invesco Biotechnology & Genome ETF
2.54%
VanEck Biotech ETF
1.79%
ROBO Global Healthcare Technology & Innovation ETF
1.51%
Pacer US Large Cap Cash Cows Growth Leaders ETF
1.26%
iShares Health Innovation Active ETF
1.21%
First Trust Health Care Alphadex Fund
0.91%
Franklin Genomic Advancements ETF
0.86%
WisdomTree International Multifactor Fund
0.72%
詳細を見る
First Trust Nasdaq Lux Digi Health Solutions ETF
比率4.04%
Global X Genomics & Biotechnology ETF
比率3.81%
Invesco Biotechnology & Genome ETF
比率2.54%
VanEck Biotech ETF
比率1.79%
ROBO Global Healthcare Technology & Innovation ETF
比率1.51%
Pacer US Large Cap Cash Cows Growth Leaders ETF
比率1.26%
iShares Health Innovation Active ETF
比率1.21%
First Trust Health Care Alphadex Fund
比率0.91%
Franklin Genomic Advancements ETF
比率0.86%
WisdomTree International Multifactor Fund
比率0.72%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
May 07, 2025
QGEN.NB Final Cash Dividend of gross USD 0.25 paid on Jul 10, 2025 going ex on Jul 02, 2025
Jul 02, 2025
Jul 10, 2025
Jul 02, 2025
株式分割
日付
種類
比率
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
日付
種類
比率
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 17, 2025
Merger
36→35
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
Jan 18, 2024
Merger
25→24.25
よくある質問
Qiagen NVの上位5名の株主は誰ですか？
Qiagen NVの上位5名の株主は以下のとおりです。
Wellington Management Company, LLPは23.33M株を保有しており、これは全体の10.76%に相当します。
MFS Investment Managementは22.91M株を保有しており、これは全体の10.56%に相当します。
The Vanguard Group, Inc.は9.33M株を保有しており、これは全体の4.30%に相当します。
T. Rowe Price International Ltdは7.52M株を保有しており、これは全体の3.47%に相当します。
DWS Investment GmbHは4.62M株を保有しており、これは全体の2.13%に相当します。
Wellington Management Company, LLPは23.33M株を保有しており、これは全体の10.76%に相当します。
MFS Investment Managementは22.91M株を保有しており、これは全体の10.56%に相当します。
The Vanguard Group, Inc.は9.33M株を保有しており、これは全体の4.30%に相当します。
T. Rowe Price International Ltdは7.52M株を保有しており、これは全体の3.47%に相当します。
DWS Investment GmbHは4.62M株を保有しており、これは全体の2.13%に相当します。
Qiagen NVの株主タイプ上位3種は何ですか？
Qiagen NVの株主タイプ上位3種は、
Wellington Management Company, LLP
MFS Investment Management
The Vanguard Group, Inc.
Wellington Management Company, LLP
MFS Investment Management
The Vanguard Group, Inc.
Qiagen NV（QGEN）の株式を保有している機関の数はいくつですか？
2025Q4時点で、Qiagen NVの株式を保有している機関は988社あり、保有株式の総市場価値は約176.43Mで、全体の85.64%を占めています。2025Q3と比較して、機関の持ち株は3.64%増加しています。
Qiagen NVの最大の収益源は何ですか？
FY2025Q3において、Consumables and Related Revenues部門がQiagen NVにとって最大の収益を生み出しており、その金額は481.20Mで、全収益の90.35%を占めています。
